Lilly Diabetes Medicine Meets Goal in Three Studies

Eli Lilly & Co.’s experimental once-weekly diabetes drug dulaglutide helped patients control their diabetes better than older treatments in three large studies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.